217.5405 Limitations on impact KRS 217.5401 to 217.5408 may have on insurance
164 words·~1 min read·
/ky/217-5405A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
coverage or health facility services -- Coverage permitted -- Approval of health
facility for use.
(1)KRS 217.5401 to 217.5408 shall not:
(a)Expand the coverage required of an insurer;
(b)Affect the requirements for insurance coverage of routine patient costs for
patients involved in approved cancer clinical trials;
(c)Require a health plan, third-party administrator, or governmental agency to
pay costs associated with the use, care, or treatment of an eligible patient with
an investigational drug, biological product, or device; or
(d)Require a hospital or health facility to provide new or additional services.
(2)A health plan, third-party administrator, or governmental agency may provide
coverage for the cost of an investigational drug, biological product, or device or the
cost of services related to the use of an investigational drug, biological product, or
device under KRS 217.5401 to 217.5408.
(3)A hospital or health facility may approve the use of an investigational drug,
biological product, or device in the hospital or health facility.